Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 1Suspended 1Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 6268Carcinoma, Renal Cell 1913Urinary Bladder Neoplasms 1670Kidney Neoplasms 930Breast Neoplasms 793Neoplasms 788Carcinoma, Transitional Cell 594Carcinoma, Non-Small-Cell Lung 524Neoplasm Metastasis 510Melanoma 485Ovarian Neoplasms 468Colorectal Neoplasms 454Lung Neoplasms 435Pancreatic Neoplasms 325Testicular Neoplasms 290Stomach Neoplasms 274Sarcoma 267Uterine Cervical Neoplasms 264Non-Muscle Invasive Bladder Neoplasms 263Head and Neck Neoplasms 241Colonic Neoplasms 217Esophageal Neoplasms 203Squamous Cell Carcinoma of Head and Neck 202Carcinoma, Hepatocellular 197Wilms Tumor 196Endometrial Neoplasms 189Recurrence 162Neuroblastoma 148Urologic Neoplasms 147Small Cell Lung Carcinoma 146

Interventions

tasquinimod 1masitinib 1Prednisone 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Metastatic Castrate Resistant Prostate Cancer × Genitourinary × Clear all
NCT03761225 2023-09-29

Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer

AB Science

Phase 3 Completed
714 enrolled
Genitourinary

Metastatic Castrate Resistant Prostate Cancer

NCT03236688 2022-10-06

Detection of ARv7 in the Plasma of Men With Advanced Metastatic Castrate Resistant Prostate Cancer (MCRP)

Exosome Diagnostics, Inc.

Suspended
30 enrolled
Genitourinary

Metastatic Castrate Resistant Prostate Cancer

NCT01732549 2019-11-22

A Proof of Concept Study of Maintenance Therapy With Tasquinimod in Patients With Metastatic Castrate-resistant Prostate Cancer Who Are Not Progressing After a First Line Docetaxel Based Chemotherapy

Ipsen

Phase 2 Terminated
144 enrolled 22 charts
Genitourinary

Metastatic Castrate Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡